BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (Secondary Data Use Study of Dabrafenib-Trametinib in "Real Life" for Non-Small Cell Lung Cancer With a BRAF V600 Mutation)

BLaDE cohort will evaluate overall survival (OS), real world progression-free survival (PFS), best response and duration of treatment in patients with advanced, metastatic Non-Small Cell Lung Cancer (NSCLC) harboring BRAF V600E or non E mutation who received dabrafeninb-trametinib combination or not. Subsequent or previous treatments (treatments delivered after or before dabrafeninb-trametinib combination will be recorded). Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.

开始日期2021-03-08

申办/合作机构

Intergroupe Francophone Cancerologie Thoracique

[+1]

NCT04452877 / Active, not recruiting临床2期

An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and efficacy of dabrafenib in combination with trametinib in Chinese patients with BRAF V600E mutation-positive metastatic Non-Small Cell Lung Cancer. The general study design has been discussed and agreed with Chinese Health Authority and is applying a similar design used for global pivotal phase II study (BRF113928).

开始日期2020-08-19

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT01336634 / Completed临床2期

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Central confirmation testing for the BRAF V600E mutation was performed and a sufficient number of subjects were enrolled with the intent of having at least 125 centrally confirmed subjects among the three cohorts.

开始日期2011-08-05

申办/合作机构

Novartis Pharmaceuticals Corp.

100 项与 BRAF V600突变阳性非小细胞肺癌相关的临床结果

登录后查看更多信息

100 项与 BRAF V600突变阳性非小细胞肺癌相关的转化医学

登录后查看更多信息

0 项与 BRAF V600突变阳性非小细胞肺癌相关的专利（医药）

登录后查看更多信息

项与 BRAF V600突变阳性非小细胞肺癌相关的文献（医药）

2024-07-29·Future Oncology

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience

Article

作者: Carrozzi, Laura ; Massa, Valentina ; Sbrana, Andrea ; Chella, Antonio ; Bernardini, Laura ; Petrini, Iacopo ; Cappelli, Sabrina

Aim: We retrospectively evaluated the effect of dabrafenib/trametinib combination in patients with BRAF-mutated non-small-cell lung cancer (NSCLC) treated in a single center from 2017 to 2022.Patients: The response and safety data of 42 patients (27 treated in first-line and 15 as second/subsequent lines) were analyzed.Results: The objective response was 73.8%, with no differences between patients undergoing first- or second-line. A longer, statistically significant median progression-free survival (PFS) was observed in patients receiving the combination in first-line vs those in the second/subsequent lines (19.9 months [95% CI: 19.7-20] vs 13.1 months [95% CI: 8.6-17.6], respectively; p = 0.012). The median overall survival (OS) was 29.9 months (95% CI: 14.1-45.7) for patients treated with the combination in first-line and 22.4 months (95% CI: 14.6-30.2) for those treated in subsequent lines. The combination was well toleratedConclusion: We confirm the efficacy of dabrafenib/trametinib in BRAF-V600-mutated NSCLC.

2024-06-01·Thoracic Cancer

Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion–insertion R) in an advanced non‐small cell lung cancer patient

Article

作者: Satozono, Yaya ; Yoshida, Tatsuya ; Ohe, Yuichiro ; Tamura, Akiko ; Inaba Higashiyama, Ryoko

AbstractAlthough dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non‐small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We report a case of 70‐year‐old woman with BRAF V600_W604 deletion–insertion R‐positive stage IVA lung adenocarcinoma, who was successfully treated with dabrafenib plus trametinib. Herein, we discuss the oncogenic role of uncommon BRAF mutations and highlight the importance of performing comprehensive genomic profiling on patients without any targetable gene alterations in companion diagnostics.

2024-04-01·Thoracic Cancer

Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD‐L1: A case report

作者: Kunimasa, Kei ; Nishino, Kazumi ; Minami, Toshiyuki ; Inoue, Takako ; Kawamura, Takahisa ; Tamiya, Motohiro

AbstractWe present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progression on immunotherapy. This case may provide an opportunity for clinicians to consider the order of administration of immunotherapy and molecular targeted therapy for BRAF V600E‐positive lung cancer.